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This study was designed to (a) estimate the contribution of tacrolimus 
nephrotoxicity to episodes of renal allograft dysfunction investigated by 
needle biopsy. (b) describe the temporal evolution of nephrotoxicity and its 
response to therapy. and (c) ascertain how often renal dysfunction is associ-
ated with concurrent extra-renal toxicity. 
Patients were selected based on a rising serum creatinine. nonnal ultra-
sound. and biopsy findings leading to a reduction in the dose of tacrolimus 
and a fall in serum creatinine. Twenty two (17%) cases of nephrotoxicity 
were identified amongst 128 consecutive kidney transplant biopsies with 
sufficient clinical data for analysis. 
There were 13 males and 9 females. 17-75 yr in age. Tacrolimus was ad-
ministered initially as a 0.075-0.1 mglkgld IV continuous infusion fol-
lowed by an oral dose of 0.15 mglkg twice daily. The onset of nephrotoxic-
ity in this study occurred 1-156 wk post-operatively. The mean baseline 
creatinine was 212.2±168.0 ~ogff (range 88.4-875.2) and rose 40.6% 
± 14.2% (range 11-66) during episodes of nephrotoxicity (p<O.OOI). The 
highest recorded plasma and whole-blood tacrolimus levels during the toxic 
episodes were respectively 2.7±0.8 nglml (range 1.1-3.5) and 31.6±10.6 
nglml (range 14.5-50.5). The drug levels were considered to be beyond the 
therapeutic range in 18n2 (82O/C:) patients. The highest tacrolimus level pre-
ceeded the rise in serum creatinine in 20 cases by an interval of 1.6± 1.8 d. 
A mean reduction in tacrolimus dosage of 41 % ± 21 o/c (range 11-89) led to 
a 86% ± 18% (range 45-1 (0) fall in the serum creatinine within 1-14 d 
(p<O.OO I). Interactions between tacrolimus and clarithromycin. diltiazem. 
or itraconazole modified the phannakokinetic parameters in three cases. Se-
rum potassium >5.0 mequiv.1I was recorded in 9/22 (41 %) cases. Three or 
more elevations in blood glucose >7.7 mmoJII (140 mgldl) were recorded in 
4111 (360/c) non-diabetic patients. Hand tremors were seen in two (9% ) cas-
es and elevated diastolic blood pressure> 90 mmHg in seven (32%) pa-
tients. 
In conclusion. tacrolimus nephrotoxicity accounted for 170/( of graft dys-
function episodes investigated by biopsy. Concurrent hyperglycemia. hy-
perkalemia. or tremors were noted in several patients. Nephrotoxicity re-
sponded well to reduction in the drug dosage. 
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Tacrolimus (Fujisawa. USA Inc.) is an effective pri-
mary immunosuppressive agent following kidney 
transplantation (1-7). It has both short -term and 
long-term advantages over conventional drugs (5). 
Thus. tacrolimus is associated with less hyperten-
sion and hypercholesterolemia than is cyclosporine 
(1). Nephrotoxicity is well recognized. but with the 
exception of the Japanese Multicenter trial (6). 
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which describes its occurrence in up to 44% of pa-
tients, its incidence has not been specifically deter-
mined in most studies on renal transplant recipients. 
The estimated incidence of tacrolimus nephrotoxici-
ty in liver transplant recipients varies from 18 to 
42% (8-11). These latter figures may not be directly 
applicable to the kidney transplant popUlation, since 
liver disease impairs tacrolimus metabolism, there-
by increasing the potential for toxicity. Furthermore, 
the diagnosis of tacrolimus nephrotoxicity in liver 
transplant patients is confounded by renal dysfunc-
tion due to sepsis. hepato-renal syndrome, hepatic 
glomerulopathy and the use of other nephrotoxic 
drugs. Heart and lung transplant recipients are not 
subject to some of these variables. but published 
studies on these patients again do not attempt to de-
fine precisely the magnitude of tacrolimus nephro-
toxicity in this clinical setting (12. 13). A detailed 
clinical description of patients undergoing tacroli-
mus-induced renal dysfunction is also lacking in 
much of the available literature. Many studies pro-
vide comparative data on groups of patients receiv-
ing either tacrolimus or cyclosporine without ana-
lyzing each episode of toxicity separately (8, 9. II. 
14-16). The purpose of the present study is there-
fore to estimate the incidence of tacrolimus nephro-
toxicity in episodes of renal allograft biopsy investi-
gated by needle biopsy, to describe its temporal evo-
lution and response to therapy in individual patients. 
and to ascertain how often it is associated with con-
current extra-renal toxicity. 
Methods 
Patients were selected over a four year period from 
July 1991 to July 1995 from a database maintained 
by the Thomas E. Starzl Transplantation Institute, 
based on the following criteria: 1. Use of tacrolimus 
as the primary immunosuppressant after kidney 
transplantation. 2. Availability of a biopsy per-
fonned for rising serum creatinine. Serum creatinine 
was performed daily in the immediate post-trans-
plant period. biweekly or weekly in the first 8-12 
wk after transplantation. and gradually reduced to 
monthly estimations thereafter. 3. Absence of acute 
rejection at biopsy leading to reduction in the dose 
of tacrolimus. 4. Fall of serum creatinine within a 2-
wk period following biopsy and reduction in immu-
nosuppression. 5. Clinical exclusion of other causes 
of graft dysfunction such as vascular and technical 
problems. 
Twenty-two (17%) cases of tacrolimus nephro-
toxicity were identified from 128 consecutive biop-
sies with adequate clinical data available for analy-
sis. The medical records of these patients were ana-
lyzed in detail with particular attention to serial 
changes in serum creatinine. serum potassium, 
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blood glucose, and alterations in the drug dosage. 
For outpatients, the last available serum creatinine 
was recorded as the baseline. In hospitalized pa-
tients the lowest value within the 14 d preceding the 
allograft biopsy was regarded as the basal serum 
creatinine. The highest serum creatinine corre-
sponding to the episode of nephrotoxicity was then 
recorded. to permit calculation of the percentage 
rise in creatinine. The post-treatment trough creati-
nine was defined as the lowest measurement record-
ed within a 14-d period following reduction of im-
munosuppression. To quantitate the therapeutic re-
sponse. the fall in creatinine was expressed as a per-
centage of the pre-treatment rise above baseline. 
The statistical significance of the initial rise and 
subsequent fall in serum creatinine was evaluated 
by the Mann-Whitney test. Trough levels of tacroli-
mus were monitored either in plasma (n=lO) or in 
whole-blood (n= 12) using published methodology 
( 17, 18). The normal therapeutic range of tacrolimus 
at our institution is considered to be 0.5-1.5 nglml 
in plasma and 5-20 nglml in whole blood. 
Results 
The clinical profile of the patients studied is pre-
sented in Table 1. There were 13 males. 9 females, 
with an age range of 17-75 yr. The indications for 
kidney transplantation were diabetes (n= 11), poly-
cystic disease (n=3). glomerulonephritis. (n=4). IgA 
nephropathy (n=2). hypertension (n= 1) and neph-
rolithiasis (n=1). After a single preoperative dose of 
0.15 mg/kg. tacrolimus was administered postopera-
tively as a 0.075--0.1 mg/kgJd intravenous continu-
ous infusion followed by an oral maintenance dose 
of 0.15 mg/kg twice daily after commencement of 
oral feeding. The onset of tacrolimus nephrotoxicity 
in this study occurred 1-156 wk postoperatively. 
The baseline creatinine was 212.2± 168.0 Ilfllol/l 
(range 88.4-875.2) and showed a mean rise of 
40.6% ± 14.2% (range 11--66) during episodes of 
nephrotoxicity (p<0.00 1). The highest mean plasma 
and whole-blood tacrolimus levels during the toxic 
episodes were 2.7 ±0.8 nglml (range 1.1-3.5) and 
31.6± 10.6 nglml (range 14.5-50.5). respectively. 
The drug levels were considered to be beyond the 
therapeutic range in 18122 (82%) patients. The high-
est tacrolimus level preceded the highest serum cre-
atinine in 16 cases by an interval of 1.6± 1.8 d. In the 
remaining two cases the serum creatinine peaked I 
and 2 d respectively prior to the highest tacrolimus 
level. The dose of tacrolimus was reduced stepwise 
until a satisfactory response in serum creatinine was 
obtained. The mean reduction was 41 % ± 21 % 
(range 11-89). and this was statistically significant 
(p<O.OO 1). No dose reduction was necessary in case 
3. since the elevated tacrolimus level fell spontane-
· ." .. "-------------
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Table 1. Clinical profile of tacrolimus nephrotoxicity in kidney transplant recipients 
# Sex AlJe Tlrne Basehne Peak Plasma WIlole blood Tacrolimus Dose Final creatine. Potassium Glucose Blood 
post-tr creatine creatine tacrolimus tacrohmus (mglday) reduction (% response), peak peak pressure 
(wi<) ((Jmolll) ((JmoIII) (nglmQ (nglmQ (%) (mequiv/l) (mmolll) (mmHg) 
1 M 53 5 168.0 221.0 2.7 45 15 176.8 (71) 4.7 11.1 188198 
2 M 52 10 168.0 309.4 35.8 10 40 212.2 (69) NA 100M NA 
3 M 44 32 221.0 459.7 14.5 8 0 159.1(100) 4.5 100M 1101110 
4 F 44 6 150.3 265.2 36.0 28 43 176.8 (77) 5.0 100M 140/60 
5 F 17 16 150.3 3094 50.5 8 66 159.1(100) 5.1 6.6 NA 
6 F 59 4 176.8 221.0 1.4 28 29 176.8(100) 4.3 13.4 168190 
7 M 40 4 132.6 203.3 17.4 30 27 159.1 (63) 4.9 100M 150/84 
8 M 43 32 106.1 203.3 1.7 18 89 159.1 (45) 5.0 6.7 136/94 
9 F 47 36 238.7 336.0 3.4 10 40 159.1(100) 5.5 100M NA 
10 M 58 114 230.1 397.8 2.4 6 66 159.1(100) 5.3 100M 1901102 
" 
F 64 2 150.3 344.8 34.7 18 71 132.6(100) 4.8 9.0 180190 
12 F 68 2 106.1 300.6 26.9 28 29 150.3 (77) 5.3' 10.3 130180 
13 F 60 4 159.1 229.8 30.6 28 36 132.6(100) 4.2 28.8 150180 
14 M 35 1 123.8 194.5 40.5 32 38 141.4 (75) 5.7 100M 158192 
15 M 52 40 88.4 265.2 19.0 11 
" 
123.8 (80) 5.0 100M 1621102 
16 M 65 10 194.5 291.7 3.3 4 50 212.2 (82) 3.7 9.6 NA 
17 F 36 156 150.3 247.5 2.7 28 14 194.5 (54) 4.1 100M 74142 
18 M 58 12 150.3 282.9 2.5 10 40 150.3(100) 5.6 100M NA 
19 M 34 32 274.0 309.4 3.5 22 36 247.5(100) NA NA NA 
20 F 75 1 875.2' 1149.2 3.3 20 20 583.4(100) 5.1 17.0 150180 
21 M 49 16 159.1 353.6 34.2 22 36 141.4(100) 5.3 12.7 160198 
22 M 51 1 495.1l' 839.8 39.6 20 75 274.0(100) 5.6 6.9 NA 
Abbreviations: 100M. insulin-dependent diabetes melitus; NA. not available; post-tr. post-transplant 
• % response refers to the fall in creatinine expressed as a percentage of the difference between the baseline creatinine and the peak creatinine. Thus. the % re-
sponse for case 1 is (221-176.SY(221-168) x100. Results between 0 and 1000/0 indicate a partial therapeutic response. Cases with a final creatinine equal to or 
lower than the baseline creatinine are all recorded as 100% response. 
• The high baseline creatinine in these patients studied 1 wk after transplantation reflects the presence of acute tubular necrosis. 
ously. In two cases a single dose of solumedrol was 
empirically administered for possible rejection prior 
to results of the biopsy becoming available. Reduc-
tion in the dose of tacrolimus led to a 86% ± 18% 
(range 45-100) fall in the serum creatinine. The 
therapeutic response generally commenced within 
1-8 d, except in case 8, where a drug interaction 
with itraconzole delayed the response to 14 d. One 
or more episodes of hyperkalemia (serum potassium 
greater than 5.0 mequiv.lL) were recorded in 9/22 
(41 %) cases within 10 d of the peak in serum creati-
nine. The actual potassium levels fluctuated some-
what, and persistent high values were not always 
observed. Three or more values of elevated blood 
glucose exceeding 7.7 mmol/l (140 mgldl) were re-
corded in 4111 (36%) non-diabetic patients. Concur-
rent use of intravenous steroids adequately ex-
plained the hyperglycemia in one patient; in the re-
mainder it was considered to be a transient manifes-
tation of FK 506 toxicity to the pancreas. Hand 
tremors attributed to tacrolimus neurotoxicity were 
seen in two (9%) cases (patients 5 and 21). The 
blood pressure readings in these patients were re-
viewed to test the notion that tacrolimus exerts its 
deleterious actions on the kidney by causing vaso-
constriction in the renal vascular bed. Elevation in 
diastolic blood pressure greater than 90 mmHg dias-
tolic was noted in seven (3217C) patients. However. 
day-to-day readings were quite variable. and no pro-
gressive rise coincided with the clinical episodes of 
nephrotoxicity. Infections were seen in 6/22 (27%) 
patients: #3 (staphylococcal pneumonia), #5 (upper 
respiratory infection), #8 (Aspergillus in brochoal-
veolar lavage), #9 (Pseudomonas infection of ab-
dominal wound), #15 (Clostridium difficile colitis) 
and #21 (acute bronchitis). 
Conventional core biopsies of the allograft were 
performed in 21 cases, and a fine needle aspiration 
biopsy in one case. Histopathological review of the 
core biopsies showed tubular vacuolization in 20121 
(95 %), myocyte vacuolization in 15121 (71 %), arte-
riolar hyalinization in 7/21 (33%), striped fibrosis in 
2121 (10%) and glomerular capillary fibrin thrombi 
in 1/21 (15%) specimens, respectively. A minimal 
interstitial infiltrate involving less than 25% of the 
surface area was present in 11121 (52%) biopsies. 
Rare foci of tubulitis (1-2 lymphocytes per tubular 
cross-section were demonstrable in 4121 (19%) cas-
es. The needle aspiration specimen showed tubular 
vacuolization with no evidence of immune activa-
tion. 
DiscussIon 
Tacrolimus allograft nephrotoxicity is widely recog-
nized. but to our knowledge, only one study has at-
tempted to estimate its incidence in kidney trans-
plant recipients (6). That investigation based the di-
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agnosis of nephrotoxicity on the clinical course of 
the patient and graft biopsy, but the actual criteria 
used were not explicitly stated. It was found that re-
nal toxicity was dependent on the dosing regimen 
and prior clinical experience with the drug. Thus, 
this study recorded a 44% incidence of nephrotoxic-
ity when tacrolimus was administered at a dose of 
0.3 mglkgld. Subsequently, with additional experi-
ence in the use of the tacrolimus a reduction in inci-
dence to 20.5% was observed (6). 
In the present study, we have observed a 17% in-
cidence of nephrotoxicity in renal transplant biosies. 
The actual incidence of nephrotoxicity is probably 
higher, since tacrolimus dosage reduction is at times 
performed without a biopsy. The initial main-
tainence dose of tacrolimus in our patients was 0.15 
mglkg twice daily. The ultimate maintainence dose, 
which was fine tuned by serial determinations of 
plasma or whole-blood levels of tacrolimus, varied 
in different patients. It is important to stress that the 
incidence of nephrotoxicity reported here refers to 
the use of tacrolimus as a primary immunosuppres-
sant after renal transplantation. In patients receiving 
intravenous tacrolimus as "rescue" therapy for re-
fractory renal or hepatic allograft rejection, initial 
nephrotoxicity is seen in nearly all patients (19-21). 
The definition of nephrotoxicity used in this study 
required a fall in creatinine in response to reduction 
in the maintainence dose of tacrolimus. Hence. only 
reversible episodes of tacrolimus nephrotoxicity 
were identified. Other investigators have described 
patients with apparently persistent nephrotoxicity 
(6. 10). However. it is not always clear whether the 
clinically non-responsive cases sustained additional 
adverse effects such as dehydration. acute tubular 
necrosis. drug reactions or transplant glomerulopa-
thy to explain the persistent graft dysfunction. Pro-
gressive drug induced renal dysfunction may occur 
in patients receiving continuous tacrolimus 
immunosuppression. since the nephrotoxic and anti-
rejection actions of this drug are mechanistically re-
lated (22). However. recognition and distinction of 
such insidiously developing toxicity from chronic 
rejection is difficult on clinical grounds. Chronic 
tacrolimus nephrotoxicity could be better studied in 
liver transplant recipients without the confounding 
influence of chronic rejection. However. these pa-
tients are predisposed to renal dysfunction caused 
by sepsis. hypotension. hepato-renal syndrome. and 
glomerulopathy associated with liver disease. all of 
which would need to be distinguished from tacroli-
mus nephrotoxicity. Studies of chronic tacrolimus 
toxicity in heart and lung transplant recipients 
should likewise control for elevations in serum crea-
tinine due to nephrotoxic antibiotics and congestive 
heart failure existing at the time of transplantation 
or developing subsequently. 
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Nephrotoxicity episodes were associated with el-
evated plasma or whole-blood in tacrolimus levels 
in 18/22 patients. In other investigations. good cor-
relation between blood tacrolimus levels and graft 
dysfunction have been observed by some authors 
(23. 24), but not by others (11, 25). The percent dose 
reduction necessary to restore allograft function var-
ied. reflecting the known variability of tacrolimus 
phannacokinetics in individual patients (26). Drug 
interactions appeared to modify further the disposi-
tion of tacrolimus in three cases. Thus, case 8, 
which required the greatest dose reduction (89%), 
was receiving itraconazole, a drug known to com-
pete with tacrolimus for metabolism by the hepatic 
microsmal cytochrome P450 system (27). Inhibition 
of tacrolimus detoxification by itraconazole would 
explain why this patient required such a drastic re-
duction in dose, and showed a lag period of 14 d be-
fore reversal of nephrotoxicity could be observed 
clinically. Diltiazem. another drug biotransformed 
by the liver microsomes (28), was used in patient 
# 10, who required a 66% dose reduction in tacroli-
mus. An extremely high level of whole-blood tac-
rolimus (50.5 nglml) was recorded in case 5. who 
received clarithromycin. a macrolide antibiotic 
structurally related to both erythromycin and tac-
rolimus. Interactions between clarithromycin and 
tacrolimus have not been previously observed to the 
best of our knowledge. but erythromycin is known 
to inhibit competitively the metabolism of tacroli-
mus by the cytochrome P-450 system. We have pre-
viously reported a kidney transplant recipient in 
whom the plasma Tacrolimus level increased from 
1.3 to 8.5 nglml within 4 d of starting erythromycin 
(29). 
The reported incidence of hyperkalemia in Tac-
rolimus treated kidney transplant patients varies 
from 27 to 67% (6, 10. 19. 30-32). Its specific inci-
dence in patients with nephrotoxicity is not men-
tioned in these studies. In the current study, one or 
more values of elevated serum potassium occurred 
in 9/22 (41 %) cases with renal dysfunction. Hyper-
kalemia as an isolated finding without other evi-
dence of impaired kidney function has been de-
scribed in 9% of patients (31). The mechanisms re-
sponsible for hyperkalemia are not well understood. 
but an effect of tacrolimus on mineralocorticoid se-
cretion and altered mineralocorticoid activity at the 
renal tubules have been proposed. Clinically. hyper-
kalemia induced by Tacrolimus usually responds 
readily to dietary restriction. potassium binding res-
ins and fludrocortisone. 
Altered glucose metabolism is another recog-
nized toxicity of Tacrolimus. Changes in the periph-
eral sensitivity to insulin and/or response of islet 
cells to blood glucose lead to hyperglycemia in 25-
35% of transplanted subjects (24, 30). Post-trans-
.........•. __ ... __ .. _-_._------
plant diabetes mellitus defined as persistently high 
blood sugar with an abnormal glucose tolerance test 
is seen in 4-22% of patients (2. 30. 33. 34). Evalua-
tion of this side effect was difficult in 11 of our cas-
es with known insulin-dependent diabetes mellitus, 
since by definition these subjects were hyperglyce-
mic even before they received Tacrolimus. Consid-
ering only patients transplanted for diseases other 
than diabetes. 4111 patients with Tacrolimus nephro-
toxicity had hyperglycemia defined as blood glu-
cose exceeding 7.7 mmol/l (140 mg/dl) on at least 
three occasions (35). Intravenous methylprednisolo-
ne had been administered empirically to one patient 
while the result of an allograft needle biopsy was 
pending. The remaining 3 patients were on stable 
maintenance doses of steroids. and the hyperglyce-
mia was likely a manifestation of Tacrolimus toxici-
ty. 
In summary. this study has shown that reversible 
Tacrolimus nephrotoxicity accounts for 17% of re-
nal allograft dysfunction episodes investigated by 
needle biopsy. The diagnosis of Tacrolimus nephro-
toxicity was based on rigorous criteria. namely a 
rise in serum creatinine requiring biopsy, absence of 
histopathologic changes of acute rejection, and clin-
ical response to reduction in the dose of Tacrolimus. 
It was noted that Tacrolimus toxicity could occur 
both early and late post-transplant. Plasma or 
whole-blood Tacrolimus levels were typically high 
at the time of clinical diagnosis, and the peak Tac-
rolimus level preceded the peak in serum creatinine. 
A reduction in dosage led to an improved serum cre-
atinine within 1-14 d. Hyperkalemia and hypergly-
cemia were noted in several cases during the epi-
sodes of nephrotoxicity. 
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